Desmoid Tumors Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

October 04 19:40 2022
Desmoid Tumors Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies  Working in the Market
Desmoid Tumors Market
DelveInsight’s Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2032 report delivers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Desmoid Tumors market report provides current treatment practices, emerging drugs, Desmoid Tumors market share of the individual therapies, current and forecasted Desmoid Tumors market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Desmoid Tumors treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Desmoid Tumors market.

Some of the key facts of the Desmoid Tumors Market:

  • According to the study conducted by Kumar et al. in 2021 titled “Desmoid tumor and molecular testing from patient-reported data in an international natural history study” Desmoid tumors are associated with CTNNB1 mutations in over 75% of cases. 


  • According to Orphanet somatic mutations in the CTNNB1 gene (3q21) encoding beta-catenin have been found in about 85 % of sporadic cases. In cases with FAP, desmoid tumors have been associated with mutations in the tumor suppressor gene APC (5q21-q22) encoding the adenomatous polyposis coli protein. Most cases are sporadic. Familial cases (5-10 %) are associated with FAP.


  • As per the study conducted by Trautmann et al. in 2020, titled “Novel pathogenic alterations in pediatric and adult desmoid type fibromatosis – A systematic analysis of 204 cases” tumor sites were categorized into (I) extra-intestinal (n=106, 58%), (II) intra-abdominal/mesenteric (n=59, 32%) and (III) abdominal/abdominal wall (n=19, 10%). All tumors within the pediatric subgroup were exclusively localized extra-intestinally. 


Got queries? Click here to know more about the Desmoid Tumors Market Landscape 

Desmoid Tumors Overview 

Desmoid tumor (DT) is called aggressive fibromatosis as it has similarities with a malignant (cancerous) tumor called fibrosarcoma. However, it is considered benign because it does not metastasize (spread) to other parts of the body. The myofibroblast is the cell responsible for the desmoid tumor. A desmoid tumor can invade surrounding tissues and be difficult to control. They can develop at any body site. Superficial desmoids tend to be less aggressive than deep desmoids (abdominal, extra-abdominal, mesenteric). These tumors look like dense scar tissue. They adhere to surrounding structures and organs and are often difficult to remove. While each child or adult may experience symptoms differently, the following are the most common symptoms of DT. The symptoms vary greatly depending on size and location which include, a painless swelling or lump, pain or soreness caused by compressed nerves or muscles, pain and obstruction of the bowels, and limping or other difficulty using the legs, feet, arms, or hands or other affected part of the body.


The cause of desmoid tumor remains unknown. Desmoid tumors may present sporadically or as a manifestation of hereditary familial adenomatous polyposis (FAP). In most patients, desmoid tumor occurs sporadically, meaning that it is not caused by predisposing genetic disease. People who develop desmoid tumors sporadically have no other APC gene-associated health problems. Repeated irritation or trauma to a certain body area, including surgical trauma, may increase the risk of developing desmoid tumor. Estrogen may also play a role in its development. 


Desmoid Tumors Epidemiological Insight:


  • According to National Organization for Rare Disorders (NORD) data desmoid tumors constitute 0.03% of all tumors. The estimated incidence in the general population is 2-4 per million people per year. Desmoid tumors are observed to be more common in persons aged 10-40 years but can occur in other age groups. Desmoid tumors can commonly occur in women after childbirth. The female: male gender ratio is 2:1. In children, the gender incidence is the same.
  • As per the American Society of Clinical Oncology (ASCO) desmoid tumors are rare, making up less than 3% of all soft-tissue tumors. Each year, approximately 900 to 1,500 people in the United States are diagnosed with a desmoid tumor. This type of tumor mostly affects people between the ages of 15 and 60 years, but it can occur at any age. It is also reported that more than 98% of patients were alive 5 years after their diagnosis. Reported recurrence rates after surgery vary widely, from approximately 20% to as high as 80%. 
  • A study conducted by Panel et al. in 2017 titled “Adult desmoid tumors: biology, management and ongoing trials” stated that a meta-analysis of five European FAP registries (2260 patients and 912 families) showed that the occurrence of desmoid tumors is approximately 10% (220/2260) and the first desmoid tumors are often in the intra-abdominal space (52.9%) or abdominal wall (24.6%). The study also indicated that desmoid tumors are typically diagnosed in young adults (peak incidence at 35–40 years), mainly in women at reproductive age, the median age at diagnosis is 31 years, Desmoid tumors comprise at least two different clinico-pathological entities: sporadic desmoid tumor and desmoid tumor associated with germline mutation of APC.

Desmoid Tumors Epidemiological Segmentation

  • Total Desmoid Tumors Incident Cases
  • Desmoid Tumors Type Specific Incident Cases
  • Desmoid Tumors Gender-Specific Cases  
  • Desmoid Tumors Age-Specific Cases
  • Desmoid Tumors Site Specific Cases
  • Desmoid Tumors Treatable Cases


Desmoid Tumors Market Outlook 


The Desmoid Tumors market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Desmoid Tumors market trends by analyzing the impact of current Desmoid Tumors therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of the Desmoid Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Desmoid Tumors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Desmoid Tumors market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @Desmoid Tumors Market Landscape

Desmoid Tumors Market Key Companies  

  • SpringWorks Therapeutics
  • Ayala Therapeutics
  • Iterion Therapeutics
  • And many more

Desmoid Tumors Market Therapies

  • Nirogacestat
  • AL102
  • Tegavivint
  • And many more

Market Drivers

  • No licensed therapy for Desmoid Tumor, which presents an opportunity for pharmaceutical companies to enter the market.
  • Market growth of Desmoid Tumors will be boosted by increased R&D and the anticipated introduction of new therapies.

Market Barriers 

  • There are challenges in conducting rare cancer clinical trials due to issues surrounding clinical trial design, patient recruitment, and analysis.
  • Lack of approved therapies poses a significant burden on Desmoid Tumors patients.
  • Owing of its rarity, Desmoid Tumors pose research obstacles, and only a few attempts have been made to develop medications for the condition.

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Desmoid Tumors Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Desmoid Tumors Market  Emerging Therapies
  • Desmoid Tumors Market Outlook
  •  Market Access and Reimbursement of Therapies
  • Market Drivers
  • Market Barriers
  •  Appendix
  • Desmoid Tumors Market Report Methodology
  • DelveInsight Capabilities
  • Disclaimer
  • About DelveInsight

Click here to read more about Desmoid Tumors Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States